Microscope
Petri Dishes
Test Tubes
Science
Male Scientist
 

Roquefort Therapeutics is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma.  The Company’s wholly owned subsidiary, Lyramid Pty Ltd (“Lyramid”), is a pre-clinical biotech company focused on developing first in class Midkine inhibiting RNA therapeutics drugs for the treatment of cancer, chronic inflammatory, autoimmune disorder and COVID-19.  Recent progress within mRNA therapeutics has led to a reduction in drug development timelines and costs, increasing the chance of early value creation.  


Through extensive research resulting in validation through publication in over 1,000 scientific journals, Lyramid has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Lyramid holds the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Lyramid’s pre-clinical programme is currently underway with an initial focus on cancer (including immunotherapy resistance) and COVID-19.

Roquefort Therapeutics is listed on the London Stock Exchange (ticker: ROQ)

Follow us on Twitter @roquefortinvest

 

AREAS OF FOCUS

We are focused on early stage opportunities in the medical biotechnology sector including:

DRUG & VACCINE DEVELOPMENT

DIAGNOSTICS

IMMUNO-THERAPY

CELL & GENE THERAPY

Closeup of a Petri Dish
Experiment
Microscope
Male Scientist
 
Closeup of a Petri Dish

"Big results require big ambitions"

Heraclitus